Construction of a Dynamic Evaluation System for Sepsis-induced Coagulation Dysfunction Based on Bayesian Data-Fusion Learning and Its Clinical Application

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2500114995

Enrollment

Unknown

Registered

2025-12-19

Start date

2026-01-01

Completion date

Unknown

Last updated

2026-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sepsis-induced coagulation dysfunction

Interventions

Observational group:None

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Age >= 18 years; 2. ICU hospitalization duration > 24 hours; 3. Meets the sepsis-3 diagnostic criteria; 4. Voluntarily signed the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Age < 18 years; 2. Pregnant or lactating women; 3. Died or discharged against medical advice within 24 hours of admission; 4. Refused to sign informed consent; 5. Primary hematological disorders (e.g., hemophilia, myelodysplastic syndromes, leukemia, etc.); 6. Malignant tumors or patients receiving chemotherapy; 7. Received heparin anticoagulation within 24 hours of ICU admission or long-term warfarin anticoagulation during the disease course; 8. Confirmed diagnosis of DIC on the day of admission.

Design outcomes

Primary

Measure	Time frame
ICU 28-day mortality;Incidence of Disseminated Intravascular Coagulation (DIC);	—

Secondary

Measure	Time frame
Basic information (age, sex, underlying diseases, etc.);Organ function assessment (SOFA score, liver, kidney, heart, lung function, lactate, etc.);Hematological parameters (complete blood count, coagulation function, platelets, etc.);Immune-coagulation mechanism-related indicators (see innovative biomarker testing);Treatment information (antimicrobial therapy, anticoagulation, organ support, etc.);	—

Measure

Time frame

Basic information (age, sex, underlying diseases, etc.);Organ function assessment (SOFA score, liver, kidney, heart, lung function, lactate, etc.);Hematological parameters (complete blood count, coagulation function, platelets, etc.);Immune-coagulation mechanism-related indicators (see innovative biomarker testing);Treatment information (antimicrobial therapy, anticoagulation, organ support, etc.);

—

Countries

China

Contacts

Public ContactYang Min

The Second Affiliated Hospital of Anhui Medical University

yangmin@ahmu.edu.cn+86 137 2104 0363

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026